

Samer Ezziddin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9149201/samer-ezziddin-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

3,911
citations

33
h-index

59
g-index

134
ext. papers

4,587
ext. citations

5.5
avg, IF

5.1
L-index

#	Paper	IF	Citations
125	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC.. <i>Cancers</i> , 2022 , 14,	6.6	1
124	PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [68Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression. <i>Diagnostics</i> , 2022 , 12, 1211	3.8	
123	Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure Preliminary Evidence of Pilot Experience. <i>Cancers</i> , 2022 , 14, 2691	6.6	0
122	Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with Lu-DOTATATE. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
121	Early molecular imaging response assessment based on determination of total viable tumor burden in [Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [Lu]Lu-PSMA-617 radioligand therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	2
120	Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [Lu]Lu-PSMA-617. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 4960-4971	8.3	5
119	Impact of prompt gamma emission of Sc on quantification in preclinical and clinical PET systems. <i>Applied Radiation and Isotopes</i> , 2021 , 170, 109599	1.7	1
118	Efficacy and Safety of [Ac]Ac-PSMA-617 Augmented [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. <i>Pharmaceutics</i> , 2021 , 13,	6.4	8
117	Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	3
116	Renal Safety of [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. <i>Cancers</i> , 2021 , 13,	6.6	9
115	Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing Lu-PSMA-617 radioligand therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 103-112	8.8	13
114	Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). <i>CardioVascular and Interventional Radiology</i> , 2021 , 44, 21-35	2.7	14
113	Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates. <i>Molecular Imaging and Biology</i> , 2021 , 23, 95-108	3.8	1
112	Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management. <i>Journal of Urology</i> , 2021 , 206, 88-96	2.5	1
111	Response Assessment and Prediction of Progression-Free Survival by Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing Lu-PSMA-617 Radioligand Therapy. <i>Biomolecules</i> , 2021 , 11,	5.9	2
110	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	3
109	Value of Combined PET Imaging with [F]FDG and [Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [Lu]Lu-PSMA-617 RLT. <i>Cancers</i> , 2021 , 13,	6.6	5

108	177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	8
107	Molecular imaging and biochemical response assessment after a single cycle of [Ac]Ac-PSMA-617/[Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [Lu]Lu-PSMA-617 monotherapy. <i>Theranostics</i> , 2021 , 11, 4050-4060	12.1	16
106	Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	3
105	Neuron-specific enolase has potential value as a biomarker for [F]FDG/[Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. <i>EJNMMI Research</i> , 2020 , 10, 52	3.6	8
104	Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17592-e17592	2.2	1
103	Determination of split renal function by PSMA imaging: comparison of Ga-PSMA-11 PET with Tc-MAG3 scintigraphy. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 10, 249-256	2.2	4
102	New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 687-694	8.8	22
101	Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2040-2041	8.8	29
100	Ac-PSMA-617/Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 721-728	8.8	65
99	Striatal dopamine transporters and cognitive function in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2020 , 142, 385-391	3.8	2
98	EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2536-2544	8.8	136
97	MIBG scintigraphy of the major salivary glands in progressive supranuclear palsy and corticobasal degeneration. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 247-248	3.6	0
96	Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 153-154	1.7	4
95	Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 730-731	1.7	
94	EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 846-859	8.8	28
93	Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1721-1730	8.8	6
92	Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes. <i>Surgical Oncology</i> , 2018 , 27, 138-145	2.5	14
91	Optimized synthesis and indium complex formation with the bifunctional chelator NODIA-Me. <i>Organic and Biomolecular Chemistry</i> , 2018 , 16, 7503-7512	3.9	5

90	MIBG scintigraphy of the major salivary glands in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2018 , 53, 112-114	3.6	0
89	Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. <i>European Radiology</i> , 2017 , 27, 966-975	8	23
88	Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1531-1541	4.9	15
87	Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017 , 34, 26-30	3.6	5
86	Radiosynoviorthesis in hemophilic arthropathy: pathologic blood pool imaging on pre-therapeutic bone scintigraphy is not a predictor of treatment success. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 461-467	8.8	5
85	Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 190-195	8.8	6
84	Efficacy of peptide receptor radionuclide therapy with Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 7, 74-83	2.2	21
83	Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1988-94	8.8	4
82	Myeloid neoplasms after chemotherapy and PRRT: myth and reality. <i>Endocrine-Related Cancer</i> , 2016 , 23, C1-7	5.7	31
81	Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. <i>European Journal of Cancer</i> , 2016 , 58, 41-51	7.5	66
80	Advances in Peptide Receptor Radionuclide Therapy. <i>Seminars in Nuclear Medicine</i> , 2016 , 46, 40-6	5.4	29
79	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2016 , 105, 364-71	6.1	42
78	The Impact of Diffusion-Weighted MRI on the Definition of Gross Tumor Volume in Radiotherapy of Non-Small-Cell Lung Cancer. <i>PLoS ONE</i> , 2016 , 11, e0162816	3.7	10
77	68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1512-1517	8.9	18
76	Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. <i>European Radiology</i> , 2015 , 25, 2693-700	8	20
75	Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1238-46	8.8	72
74	Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 370-6	8.8	46
73	Introduction of a metabolic joint asymmetry score derived from conventional bone scintigraphy. A new tool to differentiate psoriatic from rheumatoid arthritis. <i>Nuklearmedizin - NuclearMedicine</i> , 2015 , 54, 183-9	1.8	1

72	Radioembolization as a Treatment Option. <i>Deutsches Arzteblatt International</i> , 2015 , 112, 372-3	2.5	
71	Outcome of peptide receptor radionuclide therapy with ¹⁷⁷ Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 925-33	8.8	138
70	Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (¹⁷⁷ Lu)-octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 505-10	8.8	66
69	Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by ¹⁸ F-FDG PET: feasibility of a metabolic grading system. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1260-6	8.9	60
68	Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. <i>European Radiology</i> , 2014 , 24, 2482-90	8	28
67	Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with ¹⁷⁷ Lu-octreotate. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 183-90	8.9	128
66	Pretreatment Dosimetry in HCC Radioembolization with (⁹⁰ Y) Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of (^{99m} Tc)-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1215-6	8.9	16
65	Liver and lymph node metastases of prostate cancer visualized on post-therapy imaging after treatment with ¹⁸⁸ Re-HEDP. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014 , 33, 58-9	0.4	1
64	Residual activity after radioembolization of liver tumours with ⁹⁰ Y resin microspheres. A safe calculation method. <i>Nuklearmedizin - NuclearMedicine</i> , 2014 , 53, 95-8	1.8	5
63	Radioembolization with ⁹⁰ Y resin microspheres for HCC patients with extensive tumor thrombosis into the extrahepatic vessels. <i>Clinical Nuclear Medicine</i> , 2014 , 39, 305-7	1.7	
62	Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. <i>Nuklearmedizin - NuclearMedicine</i> , 2014 , 53, 54-9	1.8	25
61	Survival in patients with hepatocellular carcinoma treated with ⁹⁰ Y-microsphere radioembolization. Prediction by ¹⁸ F-FDG PET. <i>Nuklearmedizin - NuclearMedicine</i> , 2014 , 53, 39-45	1.8	26
60	Survival after ¹³¹ I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up. <i>Nuklearmedizin - NuclearMedicine</i> , 2014 , 53, 46-53	1.8	4
59	Treatment options for haemophilic arthropathy of the elbow after failed conservative therapy. A single centre experience. <i>Hamostaseologie</i> , 2014 , 34 Suppl 1, S17-22	1.9	3
58	Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 231-7	8.8	17
57	Outcome and toxicity of salvage therapy with ¹⁷⁷ Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 205-10	8.8	66
56	Diffusion-weighted imaging with acquisition of three b-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy. <i>European Radiology</i> , 2014 , 24, 267-76	8	23
55	Comment on Campana et al.: radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 171-5	8.8	1

54	Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 59-67	8.8	113
53	Diagnosis of extra-adrenal pheochromocytoma after nephrectomy. <i>Central European Journal of Urology</i> , 2014 , 67, 162-6	0.9	
52	Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 80-90	8.8	33
51	Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. <i>EJNMMI Research</i> , 2013 , 3, 82	3.6	21
50	Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 2032-8	8.9	24
49	Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1857-61	8.9	102
48	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013 , 59, 753-61	13.4	69
47	Radium-223 in prostate cancer. <i>New England Journal of Medicine</i> , 2013 , 369, 1659-60	59.2	35
46	Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate. <i>Nuklearmedizin - NuclearMedicine</i> , 2013 , 52, 170-7	1.8	10
45	Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 3, 437-45	2.2	17
44	May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 4, 80-8	2.2	4
43	Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. <i>Recent Results in Cancer Research</i> , 2013 , 194, 457-65	1.5	21
42	Correspondence (letter to the editor): Treatment option not mentioned. <i>Deutsches A&M;#x0308;rztblatt International</i> , 2013 , 110, 612	2.5	
41	The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 309-15	8.8	46
40	90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1663-9	8.9	49
39	Hypertrophy of the contralateral hepatic lobe after selective internal radiation therapy. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 44-45	1.6	1
38	Survival after accidental extrahepatic distribution of Y90 microspheres to the mesentery during a radioembolization procedure. <i>CardioVascular and Interventional Radiology</i> , 2012 , 35, 954-7	2.7	5
37	Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy. <i>Nuklearmedizin - NuclearMedicine</i> , 2012 , 51, 95-100	1.8	5

36	Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG. <i>Radiation Oncology</i> , 2012 , 7, 8	4.2	5
35	Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. <i>Clinical Nuclear Medicine</i> , 2012 , 37, 102-4	1.7	24
34	Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?. <i>Clinical Nuclear Medicine</i> , 2012 , 37, e141-7	1.7	42
33	The importance of Tc-MAA SPECT/CT for therapy planning of radioembolization in a patient treated with bevacizumab. <i>Clinical Nuclear Medicine</i> , 2012 , 37, 1129-30	1.7	12
32	Impact of dual-time-point F-18 FDG PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer. <i>Clinical Nuclear Medicine</i> , 2011 , 36, 423-8	1.7	24
31	The value of F-18 FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis. <i>Clinical Nuclear Medicine</i> , 2011 , 36, 879-83	1.7	27
30	Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 459-66	8.8	73
29	99mTc-MAA/ 90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 1281-8	8.8	19
28	Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with 99mTc-MAA accumulation in the anterior abdominal wall?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 1477-84	8.8	29
27	Successful radiopeptide targeting of metastatic anaplastic meningioma: case report. <i>Radiation Oncology</i> , 2011 , 6, 94	4.2	24
26	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. <i>Hepatology</i> , 2011 , 54, 868-78	11.2	458
25	Research reporting standards for radioembolization of hepatic malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2011 , 22, 265-78	2.4	163
24	Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1197-203	8.9	47
23	Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1721-6	8.9	56
22	Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1063-7	8.9	28
21	The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1206-12	8.9	92
20	Radioembolization of liver tumors with yttrium-90 microspheres. <i>Seminars in Nuclear Medicine</i> , 2010 , 40, 105-21	5.4	132
19	131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. <i>Seminars in Nuclear Medicine</i> , 2010 , 40, 153-63	5.4	68

18	Dual-time F-18 FDG-PET/CT imaging for diagnosis of occult non-Hodgkin lymphoma in a patient with esophageal cancer. <i>Clinical Nuclear Medicine</i> , 2009 , 34, 168-70	1.7	7
17	Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. <i>Melanoma Research</i> , 2008 , 18, 346-52	3.3	51
16	Splenic infarction mimicking a necrotizing metastasis of malignant melanoma on F-18 FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2008 , 33, 571-2	1.7	6
15	Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 803-809	7	3
14	False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. <i>Lung Cancer</i> , 2007 , 58, 418-21	5.9	40
13	Therapy of hepatocellular carcinoma with 131I-lipiodol: patient dosimetry. <i>Nuklearmedizin - Nuclear Medicine</i> , 2007 , 46, 192-7	1.8	1
12	Osteoporosis in haemophilia - an underestimated comorbidity?. <i>Haemophilia</i> , 2007 , 13, 79-84	3.3	89
11	Single- vs. dual-head SPECT for detection of myocardial ischemia and viability in a large study population. <i>Clinical Imaging</i> , 2007 , 31, 228-33	2.7	2
10	Somatostatin receptor scintigraphy in the follow-up of myasthenia gravis. <i>Neurological Sciences</i> , 2007 , 28, 175-80	3.5	1
9	111In-pentetreotide scintigraphy in medulloblastoma: a comparison with magnetic resonance imaging. <i>Acta Oncologica</i> , 2007 , 46, 111-7	3.2	11
8	Impact of thyroid metabolism on the course of INR levels in a patient with systemic anticoagulation suffering from amiodarone-induced thyrotoxicosis. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007 , 115, 606-9	2.3	0
7	Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 608-12	8.8	14
6	Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine. <i>British Journal of Radiology</i> , 2006 , 79, e84-7	3.4	3
5	Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 223-33	8.9	56
4	The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004 , 130, 649-56	4.9	27
3	Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004 , 31, 797	8.8	47
2	Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2869-75	2.2	138
1	Radioiodine therapy in Graves disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002 , 29, 1118-24	8.8	66

